- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- The State Autonomous Healthcare Institution of the Sverdlovsk Region «Sverdlovsk Regional Oncological Dispensary»
The State Autonomous Healthcare Institution of the Sverdlovsk Region «Sverdlovsk Regional Oncological Dispensary»
The State Autonomous Healthcare Institution of the Sverdlovsk Region «Sverdlovsk Regional Oncological Dispensary» is the leading medical center in the region providiry specialized high-tech healthcare assistance for the oncological patients at Sverdlovsk region.
The Sverdlovsk Regional Oncological Dispensary is the participant of the national project «Healthcare», the federal project «Fight against oncological diseases», the largest oncological clinic in the Middle Urals and the head institution of the oncological service of the Sverdlovsk region. All modern methods for the diagnostic and treatment of available on the base of the oncological center.
Every year, medical staff performs over 22 400 surgeries, 29 200 chemotherapy courses and 8 100 radiation therapy courses actually.
The potential of medicine grows. The issues of early diagnosis and treatment of malignant neoplasms are of particular interest. Sverdlovsk oncologists improve their knowledge and skills at all-Russian and international scientific forums, conferences, symposiums. Specialists of oncological dispensary teach general practicants in new methods of treating and diagnosing oncological diseases, and conduct classes for patients and their relatives.
The oncological dispensary aim is to make modern medical oncological care affordable and of high quality. The Sverdlovsk Regional Oncology Center is focused on the highest world standards.
The Sverdlovsk Regional Oncological Dispensary branches in Yekaterinburg, Branch №1 in the city of Nizhny Tagil and Branch №2 in the city of Kamensk-Uralsky.
